The role of radiotherapy in the management of patients with diffuse low grade glioma
- 2.1k Downloads
What is the optimal role of external beam radiotherapy in the management of adult patients with newly diagnosed low-grade glioma (LGG) in terms of improving outcome (i.e. survival, complications, seizure control or other reported outcomes of interest)?
Which radiation strategies (dose, timing, fractionation, stereotactic radiation, brachytherapy, chemotherapy) improve outcomes compared to standard external beam radiation therapy in the initial management of low grade gliomas in adults?
Do specific factors (e.g. age, volume, extent of resection, genetic subtype) identify subgroups with better outcomes following radiation therapy than the general population of adults with newly diagnosed low-grade gliomas?
These recommendations apply to adults with newly diagnosed diffuse LGG.
Outcomes in adult patients with newly diagnosed low grade glioma treated with radiotherapy
Level I Radiotherapy is recommended in the management of newly diagnosed low-grade glioma in adults to prolong progression free survival, irrespective of extent of resection.
Level II Radiotherapy is recommended in the management of newly diagnosed low grade glioma in adults as an equivalent alternative to observation in preserving cognitive function, irrespective of extent of resection.
Level III Radiotherapy is recommended in the management of newly diagnosed low grade glioma in adults to improve seizure control in patients with epilepsy and subtotal resection.
Level III Radiotherapy is recommended in the management of newly diagnosed low-grade glioma in adults to prolong overall survival in patients with subtotal resection.
Level III Consideration of the risk of radiation induced morbidity, including cognitive decline, imaging abnormalities, metabolic dysfunction and malignant transformation, is recommended when the delivery of radiotherapy is selected in the management of newly diagnosed low-grade glioma in adults.
Strategies of radiotherapy in adult patients with newly diagnosed low grade glioma
Level I Lower dose radiotherapy is recommended as an equivalent alternative to higher dose immediate postoperative radiotherapy (45–50.4 vs. 59.4–64.8 Gy) in the management of newly diagnosed low-grade glioma in adults with reduced toxicity.
Level III Delaying radiotherapy until recurrence or progression is recommended as an equivalent alternative to immediate postoperative radiotherapy in the management of newly diagnosed low-grade glioma in adults but may result in shorter time to progression.
Level III The addition of chemotherapy to radiotherapy is not recommended over whole brain radiotherapy alone in the management of low-grade glioma, as it provides no additional survival benefit.
Level III Limited-field radiotherapy is recommended over whole brain radiotherapy in the management of low-grade glioma.
Level III Either stereotactic radiosurgery or brachytherapy are recommended as acceptable alternatives to external radiotherapy in selected patients.
Prognostic factors in adult patients with newly diagnosed low grade glioma treated with radiotherapy
Level II It is recommended that age greater than 40 years, astrocytic pathology, diameter greater than 6 cm, tumor crossing the midline and preoperative neurological deficit be considered as negative prognostic indicators when predicting overall survival in adult low grade glioma patients treated with radiotherapy.
Level II It is recommended that smaller tumor size, extent of surgical resection and higher mini-mental status exam be considered as positive prognostic indicators when predicting overall survival and progression free survival in patients in adult low grade glioma patients treated with radiotherapy.
Level III It is recommended that seizures at presentation, presence of oligodendroglial histological component and 1p19q deletion (along with additional relevant factors—see Table 1) be considered as positive prognostic indicators when predicting response to radiotherapy in adults with low grade gliomas.
Level III It is recommended that increasing age, decreasing performance status, decreasing cognition, presence of astrocytic histological component (along with additional relevant factors (see Tables 1, 2) be considered as negative prognostic indicators when predicting response to radiotherapy.
KeywordsLow grade glioma Astrocytoma Oligodendroglioma Radiation Radiation sensitizer Systematic review Practice guideline
We acknowledge the significant contributions of Laura Mitchell, Senior Manager of Clinical Practice Guidelines for the CNS, the AANS/CNS Joint Guidelines Committee (JGC) for their review, comments and suggestions, and Anne Woznica and Mary Bodach for their assistance with the literature searches. We also acknowledge the following individual JGC members for their contributions throughout the review process: Kevin Cockroft, MD, Sepideh Amin-Hanjani, MD, Kimon Bekelis, MD, Isabelle Germano, MD, Daniel Hoh, MD, Steven Hwang, MD, Cheerag Dipakkumar Upadhyaya, MD, Christopher Winfree, MD, and Brad Zacharia, MD.
Dr. Parney is a consultant for Agenus, Inc. Dr. Kalkanis is a consultant for Arbor and Varian. Dr. Olson is a consultant for the American Cancer Society; has received research funding from the National Cancer Institute, Genentech, and Millennium; and has received investigational drug provision from Merck.
- 1.Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, Darcel F, Stenning S, Pierart M, Van Glabbeke M (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52:316–324PubMedCrossRefGoogle Scholar
- 2.Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van Glabbeke M (1996) A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 36:549–556PubMedCrossRefGoogle Scholar
- 3.Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH, Nordman E, Silvestre ME, Pierart M, Karim AB (1998) Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer 34:1902–1909PubMedCrossRefGoogle Scholar
- 4.Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R, Curran W, Abrams R (2002) Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20:2267–2276PubMedCrossRefGoogle Scholar
- 5.Brown PD, Buckner JC, O’Fallon JR, Iturria NL, Brown CA, O’Neill BP, Scheithauer BW, Dinapoli RP, Arusell RM, Curran WJ, Abrams R, Shaw EG (2003) Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 21:2519–2524. doi: 10.1200/jco.2003.04.172 PubMedCrossRefGoogle Scholar
- 6.Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW, Dekker AW, Jolles J, Slotman BJ, Struikmans H, Taphoorn MJ (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360:1361–1368PubMedCrossRefGoogle Scholar
- 12.van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985–990PubMedCrossRefGoogle Scholar
- 17.Jeremic B, Milicic B, Grujicic D, Samardzic M, Antunovic V, Dagovic A, Aleksandrovic J, Stojanovic M (2003) Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma: a 10-year update of a phase II study. Int J Radiat Oncol Biol Phys 57:465–471PubMedCrossRefGoogle Scholar
- 31.Schnell O, Scholler K, Ruge M, Siefert A, Tonn JC, Kreth FW (2008) Surgical resection plus stereotactic 125I brachytherapy in adult patients with eloquently located supratentorial WHO grade II glioma—feasibility and outcome of a combined local treatment concept. J Neurol 255:1495–1502. doi: 10.1007/s00415-008-0948-x PubMedCrossRefGoogle Scholar
- 46.Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman RH, Beute GN, Sluimer JD, Slotman BJ, Reijneveld JC, Heimans JJ (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8:810–818. doi: 10.1016/s1474-4422(09)70204-2 PubMedCrossRefGoogle Scholar
- 47.Gondi V, Hermann BP, Mehta MP, Tome WA (2012) Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys 83:e487–e493. doi: 10.1016/j.ijrobp.2011.10.021 PubMedCentralPubMedCrossRefGoogle Scholar
- 48.Jalali R, Mallick I, Dutta D, Goswami S, Gupta T, Munshi A, Deshpande D, Sarin R (2010) Factors influencing neurocognitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal radiotherapy. Int J Radiat Oncol Biol Phys 77:974–979. doi: 10.1016/j.ijrobp.2009.06.025 PubMedCrossRefGoogle Scholar
- 52.Laack NN, Brown PD, Ivnik RJ, Furth AF, Ballman KV, Hammack JE, Arusell RM, Shaw EG, Buckner JC (2005) Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 63:1175–1183. doi: 10.1016/j.ijrobp.2005.04.016 PubMedCrossRefGoogle Scholar
- 53.Brown PD, Buckner JC, O’Fallon JR, Iturria NL, O’Neill BP, Brown CA, Scheithauer BW, Dinapoli RP, Arusell RM, Curran WJ, Abrams R, Shaw EG (2004) Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys 59:117–125. doi: 10.1016/j.ijrobp.2003.10.040 PubMedCrossRefGoogle Scholar
- 59.Daniels TB, Brown PD, Felten SJ, Wu W, Buckner JC, Arusell RM, Curran WJ, Abrams RA, Schiff D, Shaw EG (2011) Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys 81:218–224. doi: 10.1016/j.ijrobp.2010.05.003 PubMedCentralPubMedCrossRefGoogle Scholar
- 60.Leighton C, Fisher B, Macdonald D, Stitt L, Bauman G, Cairncross J (2007) The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection. J Neurooncol 82:165–170. doi: 10.1007/s11060-006-9141-1 PubMedCrossRefGoogle Scholar
- 63.Eyre HJ, Crowley JJ, Townsend JJ, Eltringham JR, Morantz RA, Schulman SF, Quagliana JM, Al-Sarraf M (1993) A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 78:909–914. doi: 10.3171/jns.1993.78.6.0909 PubMedCrossRefGoogle Scholar
- 64.Lo SS, Cho KH, Hall WA, Hernandez WL, Kossow RJ, Lee CK, Clark HB (2001) Does the extent of surgery have an impact on the survival of patients who receive postoperative radiation therapy for supratentorial low-grade gliomas? Int J Cancer 96(Suppl):71–78. doi: 10.1002/ijc.10359 PubMedCrossRefGoogle Scholar
- 72.Touboul E, Schlienger M, Buffat L, Balosso J, Minne JF, Schwartz LH, Pene F, Masri-Zada T, Lot G, Devaux B (1995) Radiation therapy with or without surgery in the management of low-grade brain astrocytomas. A retrospective study of 120 patients. Bull du Cancer Radiother 82:388–395CrossRefGoogle Scholar
- 80.Kaloshi G, Psimaras D, Mokhtari K, Dehais C, Houillier C, Marie Y, Laigle-Donadey F, Taillibert S, Guillevin R, Martin-Duverneuil N, Sanson M, Hoang-Xuan K, Delattre JY (2009) Supratentorial low-grade gliomas in older patients. Neurology 73:2093–2098. doi: 10.1212/WNL.0b013e3181c6781e PubMedCrossRefGoogle Scholar
- 86.Jubelirer SJ, Rubin M, Shim C (1993) An analysis of 38 cases of low-grade cerebral astrocytoma in adults. West Va Med J 89:102–105Google Scholar
- 97.Fitzek MM, Thornton AF, Gt Harsh, Rabinov JD, Munzenrider JE, Lev M, Ancukiewicz M, Bussiere M, Hedley-Whyte ET, Hochberg FH, Pardo FS (2001) Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: results of an institutional phase I/II trial. Int J Radiat Oncol Biol Phys 51:131–137PubMedCrossRefGoogle Scholar
- 99.Pu AT, Sandler HM, Radany EH, Blaivas M, Page MA, Greenberg HS, Junck L, Ross DA (1995) Low grade gliomas: preliminary analysis of failure patterns among patients treated using 3D conformal external beam irradiation. Int J Radiat Oncol Biol Phys 31:461–466. doi: 10.1016/0360-3016(94)00400-f PubMedCrossRefGoogle Scholar
- 100.Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, Cajavec-Bernard B, Idbaih A, Psimaras D, Dainese L, Pallud J, Cartalat-Carel S, Delattre JY, Honnorat J, Grenier E, Ducray F (2012) A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clin Cancer Res 18:5071–5080. doi: 10.1158/1078-0432.CCR-12-0084 PubMedCrossRefGoogle Scholar
- 101.Pallud J, Llitjos JF, Dhermain F, Varlet P, Dezamis E, Devaux B, Souillard-Scemama R, Sanai N, Koziak M, Page P, Schlienger M, Daumas-Duport C, Meder JF, Oppenheim C, Roux FX (2012) Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol 14:496–505. doi: 10.1093/neuonc/nos069 PubMedCentralPubMedCrossRefGoogle Scholar
- 102.Fathi AR, Vassella E, Arnold M, Curschmann J, Reinert M, Vajtai I, Weis J, Deiana G, Mariani L (2007) Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status. Strahlenther Onko 183:517–522. doi: 10.1007/s00066-007-1673-6 CrossRefGoogle Scholar